Skip to main content
Erschienen in: Gastric Cancer 4/2023

10.04.2023 | Original Article

Molecular profile of poorly cohesive gastric carcinoma with special reference to survival

verfasst von: Yusuke Koseki, Keiichi Hatakeyama, Masanori Terashima, Takeshi Nagashima, Kenichi Urakami, Keiichi Ohshima, Daisuke Aizawa, Takashi Sugino, Kenichiro Furukawa, Keiichi Fujiya, Yutaka Tanizawa, Etsuro Bando, Yukiyasu Okamura, Yasuto Akiyama, Ken Yamaguchi

Erschienen in: Gastric Cancer | Ausgabe 4/2023

Einloggen, um Zugang zu erhalten

Abstract

Background

Patients with poorly cohesive gastric carcinoma (PCC) are known to have poor survival. However, detailed molecular biology of PCC has not been elucidated, except for mutations in CDH1 and RHOA. Additionally, the molecular profiles of signet-ring cell carcinoma (SRC) have not been fully investigated. We aimed to investigate the association between molecular profiles and survival in PCC and PCC subtypes.

Methods

The present study included 455 patients with gastric adenocarcinoma underwent radical gastrectomy. Whole-exome sequencing and gene expression profiling were conducted. Patients were classified according to the WHO classification as PCC or non-PCC, with PCC being further classified into SRC, combined, and PCC not-otherwise-specified (NOS). Clinicopathological factors and survival were compared with molecular profiles.

Results

Of the patients, 159 were classified with PCC, while 296 were classified with non-PCC. Among PCC, 44 were classified with SRC, 64 with combined, and 51 with PCC-NOS. Mutations in CDH1 and RHOA were remarkably more frequent in PCC than in non-PCC. PCC had worse overall survival (OS) and disease-specific survival (DSS) compared to non-PCC. For PCC, the SRC group had good OS and DSS, whereas PCC-NOS classification with CDH1 mutations was associated with extremely poor survival. In the PCC-NOS and combined groups, patients with mutations in the extracellular domain 1 of CDH1 had poor survival.

Conclusions

Our findings suggest that PCC has poorer survival than non-PCC. Accumulation of CDH1 and RHOA mutations are unique profiles in PCC. Among PCC, CDH1 mutations may play a crucial role in the survival of non-SRC PCC.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.CrossRefPubMed Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.CrossRefPubMed
2.
Zurück zum Zitat Laurén PA, Nevalainen TJ. Epidemiology of intestinal and diffuse types of gastric carcinoma. A time-trend study in Finland with comparison between studies from high- and low-risk areas. Cancer. 1993;71:2926–33.CrossRefPubMed Laurén PA, Nevalainen TJ. Epidemiology of intestinal and diffuse types of gastric carcinoma. A time-trend study in Finland with comparison between studies from high- and low-risk areas. Cancer. 1993;71:2926–33.CrossRefPubMed
3.
Zurück zum Zitat Henson DE, Dittus C, Younes M, Nguyen H, Albores-Saavedra J. Differential trends in the intestinal and diffuse types of gastric carcinoma in the United States, 1973–2000: increase in the signet ring cell type. Arch Pathol Lab Med. 2004;128:765–70.CrossRefPubMed Henson DE, Dittus C, Younes M, Nguyen H, Albores-Saavedra J. Differential trends in the intestinal and diffuse types of gastric carcinoma in the United States, 1973–2000: increase in the signet ring cell type. Arch Pathol Lab Med. 2004;128:765–70.CrossRefPubMed
4.
Zurück zum Zitat Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma 3rd English edition. Gastric Cancer. 2011;14:101–12.CrossRef Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma 3rd English edition. Gastric Cancer. 2011;14:101–12.CrossRef
5.
Zurück zum Zitat Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma. 15th ed. Tokyo: Kanehara Shuppan; 2017. Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma. 15th ed. Tokyo: Kanehara Shuppan; 2017.
6.
Zurück zum Zitat WHO Classification of Tumours Editorlal Board. WHO classification of tumours. Digestive system tumours. 5th ed. Geneva: World Health Organization; 2019. WHO Classification of Tumours Editorlal Board. WHO classification of tumours. Digestive system tumours. 5th ed. Geneva: World Health Organization; 2019.
7.
Zurück zum Zitat Voron T, Messager M, Duhamel A, Lefevre J, Mabrut JY, Goere D, et al. Is signet-ring cell carcinoma a specific entity among gastric cancers. Gastric Cancer. 2016;19:1027–40.CrossRefPubMed Voron T, Messager M, Duhamel A, Lefevre J, Mabrut JY, Goere D, et al. Is signet-ring cell carcinoma a specific entity among gastric cancers. Gastric Cancer. 2016;19:1027–40.CrossRefPubMed
8.
Zurück zum Zitat Chon HJ, Hyung WJ, Kim C, Park S, Kim JH, Park CH, et al. Differential prognostic implications of gastric signet ring cell carcinoma: stage adjusted analysis from a single high-volume center in Asia. Ann Surg. 2017;265:946–53.CrossRefPubMed Chon HJ, Hyung WJ, Kim C, Park S, Kim JH, Park CH, et al. Differential prognostic implications of gastric signet ring cell carcinoma: stage adjusted analysis from a single high-volume center in Asia. Ann Surg. 2017;265:946–53.CrossRefPubMed
9.
Zurück zum Zitat Bonnot PE, Lintis A, Mercier F, Benzerdjeb N, Passot G, Pocard M, et al. the FREGAT and BIG-RENAPE networks, prognosis of poorly cohesive gastric cancer after complete cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (CYTO-CHIP study). Br J Surg. 2021;108(10):1225–35.CrossRefPubMed Bonnot PE, Lintis A, Mercier F, Benzerdjeb N, Passot G, Pocard M, et al. the FREGAT and BIG-RENAPE networks, prognosis of poorly cohesive gastric cancer after complete cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (CYTO-CHIP study). Br J Surg. 2021;108(10):1225–35.CrossRefPubMed
10.
Zurück zum Zitat Wang K, Yuen ST, Xu J, et al. Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer. Nature Genet. 2014;46:573–82.CrossRefPubMed Wang K, Yuen ST, Xu J, et al. Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer. Nature Genet. 2014;46:573–82.CrossRefPubMed
11.
Zurück zum Zitat Bencivenga M, Simbolo M, Ciaparrone C, Vicentini C, Torroni L, Piredda ML, et al. Poorly cohesive gastric cancers showing the transcriptomic hallmarks of epithelial-mesenchymal transition behave aggressively. Ann Surg. 2022;276:822–9.CrossRefPubMed Bencivenga M, Simbolo M, Ciaparrone C, Vicentini C, Torroni L, Piredda ML, et al. Poorly cohesive gastric cancers showing the transcriptomic hallmarks of epithelial-mesenchymal transition behave aggressively. Ann Surg. 2022;276:822–9.CrossRefPubMed
12.
Zurück zum Zitat Kakiuchi M, Nishizawa T, Ueda H, et al. Recurrent gain-of-function mutations of RHOA in diffuse-type gastric carcinoma. Nat Genet. 2014;46:583–7.CrossRefPubMed Kakiuchi M, Nishizawa T, Ueda H, et al. Recurrent gain-of-function mutations of RHOA in diffuse-type gastric carcinoma. Nat Genet. 2014;46:583–7.CrossRefPubMed
13.
Zurück zum Zitat Kwon CH, Kim YK, Lee S, et al. Gastric poorly cohesive carcinoma: a correlative study of mutational signatures and prognostic significance based on histopathological subtypes. Histopathology. 2018;72:556–68.CrossRefPubMed Kwon CH, Kim YK, Lee S, et al. Gastric poorly cohesive carcinoma: a correlative study of mutational signatures and prognostic significance based on histopathological subtypes. Histopathology. 2018;72:556–68.CrossRefPubMed
14.
Zurück zum Zitat Bencivenga M, Treppiedi E, Dal Cero M, Torroni L, Verlato G, Iglesias M, et al. The amount of signet ring cells is significantly associated with tumour stage and survival in gastric poorly cohesive tumours. J Surg Oncol. 2020;121:1084–9.CrossRefPubMed Bencivenga M, Treppiedi E, Dal Cero M, Torroni L, Verlato G, Iglesias M, et al. The amount of signet ring cells is significantly associated with tumour stage and survival in gastric poorly cohesive tumours. J Surg Oncol. 2020;121:1084–9.CrossRefPubMed
15.
Zurück zum Zitat Roviello F, Marano L, Ambrosio MR, Resca L, D’Ignazio A, Petrelli F, et al. Signet ring cell percentage in poorly cohesive gastric cancer patients: a potential novel predictor of survival. Eur J Surg Oncol. 2022;48:561–9.CrossRefPubMed Roviello F, Marano L, Ambrosio MR, Resca L, D’Ignazio A, Petrelli F, et al. Signet ring cell percentage in poorly cohesive gastric cancer patients: a potential novel predictor of survival. Eur J Surg Oncol. 2022;48:561–9.CrossRefPubMed
16.
Zurück zum Zitat Nakamura K, Eto K, Iwagami S, Ogawa K, Sawayama H, Ishimoto T, Miyamoto Y, Yoshida N, Baba H, et al. Clinicopathological characteristics and prognosis of poorly cohesive cell subtype of gastric cancer. Int J Clin Oncol. 2022;27:512–9.CrossRefPubMed Nakamura K, Eto K, Iwagami S, Ogawa K, Sawayama H, Ishimoto T, Miyamoto Y, Yoshida N, Baba H, et al. Clinicopathological characteristics and prognosis of poorly cohesive cell subtype of gastric cancer. Int J Clin Oncol. 2022;27:512–9.CrossRefPubMed
17.
Zurück zum Zitat The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513:202–9.CrossRef The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513:202–9.CrossRef
18.
Zurück zum Zitat Cristescu R, Lee J, Nebozhyn M, Kim KM, Ting JC, Wong SS, et al. Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat Med. 2015;21:449–56.CrossRefPubMed Cristescu R, Lee J, Nebozhyn M, Kim KM, Ting JC, Wong SS, et al. Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat Med. 2015;21:449–56.CrossRefPubMed
19.
Zurück zum Zitat Yamaguchi K, Urakami K, Ohshima K, Mochizuki T, Akiyama Y, Uesaka K, et al. Implementation of individualized medicine for cancer patients by multiomics-based analyses-the Project HOPE. Biomed Res. 2014;35:407–12.CrossRefPubMed Yamaguchi K, Urakami K, Ohshima K, Mochizuki T, Akiyama Y, Uesaka K, et al. Implementation of individualized medicine for cancer patients by multiomics-based analyses-the Project HOPE. Biomed Res. 2014;35:407–12.CrossRefPubMed
20.
Zurück zum Zitat Nagashima T, Yamaguchi K, Urakami K, Shimoda Y, Ohnami S, Ohshima K, et al. Japanese Version of The Cancer Genome Atlas, JCGA, established using fresh frozen tumors obtained from 5143 cancer patients. Cancer Sci. 2020;111:687–99.CrossRefPubMedPubMedCentral Nagashima T, Yamaguchi K, Urakami K, Shimoda Y, Ohnami S, Ohshima K, et al. Japanese Version of The Cancer Genome Atlas, JCGA, established using fresh frozen tumors obtained from 5143 cancer patients. Cancer Sci. 2020;111:687–99.CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Furukawa K, Hatakeyama K, Terashima M, Nagashima T, Urakami K, Ohshima K, et al. Molecular classification of gastric cancer predicts survival in patients undergoing radical gastrectomy based on project HOPE. Gastric Cancer. 2022;25:138–48.CrossRefPubMed Furukawa K, Hatakeyama K, Terashima M, Nagashima T, Urakami K, Ohshima K, et al. Molecular classification of gastric cancer predicts survival in patients undergoing radical gastrectomy based on project HOPE. Gastric Cancer. 2022;25:138–48.CrossRefPubMed
22.
Zurück zum Zitat Ajani JA, In H, Sano T, et al. Stomach. In: Amin MB, editor., et al., AJCC cancer staging manual. 8th ed. New York: Springer-Verlag; 2016. p. 24. Ajani JA, In H, Sano T, et al. Stomach. In: Amin MB, editor., et al., AJCC cancer staging manual. 8th ed. New York: Springer-Verlag; 2016. p. 24.
23.
Zurück zum Zitat Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2018 (5th edition). Gastric Cancer. 2021;24:1–21.CrossRef Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2018 (5th edition). Gastric Cancer. 2021;24:1–21.CrossRef
24.
Zurück zum Zitat Mariette C, Carneiro F, Grabsch HI, van der Post RS, Allum W, de Manzoni G. Consensus on the pathological definition and classification of poorly cohesive gastric carcinoma. Gastric Cancer. 2019;22:1–9.CrossRefPubMed Mariette C, Carneiro F, Grabsch HI, van der Post RS, Allum W, de Manzoni G. Consensus on the pathological definition and classification of poorly cohesive gastric carcinoma. Gastric Cancer. 2019;22:1–9.CrossRefPubMed
25.
Zurück zum Zitat Kim SK, Kim HJ, Park JL, Heo H, Kim SY, Lee SI, et al. Identification of a molecular signature of prognostic subtypes in diffuse-type gastric cancer. Gastric Cancer. 2020;23:473–82.CrossRefPubMed Kim SK, Kim HJ, Park JL, Heo H, Kim SY, Lee SI, et al. Identification of a molecular signature of prognostic subtypes in diffuse-type gastric cancer. Gastric Cancer. 2020;23:473–82.CrossRefPubMed
26.
Zurück zum Zitat Wang R, Song S, Harada K, Ghazanfari Amlashi F, Badgwell B, Pizzi MP, et al. Multiplex profiling of peritoneal metastases from gastric adenocarcinoma identified novel targets and molecular subtypes that predict treatment response. Gut. 2020;69:18–31.CrossRefPubMed Wang R, Song S, Harada K, Ghazanfari Amlashi F, Badgwell B, Pizzi MP, et al. Multiplex profiling of peritoneal metastases from gastric adenocarcinoma identified novel targets and molecular subtypes that predict treatment response. Gut. 2020;69:18–31.CrossRefPubMed
27.
Zurück zum Zitat Cheng J, He J, Wang S, Zhao Z, Yan H, Guan Q, et al. Biased influences of low tumor purity on mutation detection in cancer. Front Mol Biosci. 2020;7:533196.CrossRefPubMedPubMedCentral Cheng J, He J, Wang S, Zhao Z, Yan H, Guan Q, et al. Biased influences of low tumor purity on mutation detection in cancer. Front Mol Biosci. 2020;7:533196.CrossRefPubMedPubMedCentral
28.
Zurück zum Zitat Sohn BH, Hwang JE, Jang HJ, Lee HS, Oh SC, Shim JJ, et al. Clinical significance of four molecular subtypes of gastric cancer identified by the cancer genome atlas project. Clin Cancer Res. 2017;23:4441–9.CrossRefPubMedPubMedCentral Sohn BH, Hwang JE, Jang HJ, Lee HS, Oh SC, Shim JJ, et al. Clinical significance of four molecular subtypes of gastric cancer identified by the cancer genome atlas project. Clin Cancer Res. 2017;23:4441–9.CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat Polom K, Marano L, Marrelli D, De Luca R, Roviello G, Savelli V, et al. Meta-analysis of microsatellite instability in relation to clinicopathological characteristics and overall survival in gastric cancer. Br J Surg. 2018;105:159–67.CrossRefPubMed Polom K, Marano L, Marrelli D, De Luca R, Roviello G, Savelli V, et al. Meta-analysis of microsatellite instability in relation to clinicopathological characteristics and overall survival in gastric cancer. Br J Surg. 2018;105:159–67.CrossRefPubMed
30.
Zurück zum Zitat Lazăr D, Tăban S, Ardeleanu C, Dema A, Sporea I, Cornianu M, et al. The immunohistochemical expression of E-cadherin in gastric cancer; correlations with clinicopathological factors and patients’ survival. Rom J Morphol Embryol. 2008;49:459–67.PubMed Lazăr D, Tăban S, Ardeleanu C, Dema A, Sporea I, Cornianu M, et al. The immunohistochemical expression of E-cadherin in gastric cancer; correlations with clinicopathological factors and patients’ survival. Rom J Morphol Embryol. 2008;49:459–67.PubMed
31.
Zurück zum Zitat Leckband D, Prakasam A. Mechanism and dynamics of cadherin adhesion. Annu Rev Biomed Eng. 2006;8:259–8732.CrossRefPubMed Leckband D, Prakasam A. Mechanism and dynamics of cadherin adhesion. Annu Rev Biomed Eng. 2006;8:259–8732.CrossRefPubMed
32.
33.
Zurück zum Zitat Handschuh G, Luber B, Hutzler P, Höfler H, Becker KF. Single amino acid substitutions in conserved extracellular domains of E-cadherin differ in their functional consequences. J Mol Biol. 2001;314:445–54.CrossRefPubMed Handschuh G, Luber B, Hutzler P, Höfler H, Becker KF. Single amino acid substitutions in conserved extracellular domains of E-cadherin differ in their functional consequences. J Mol Biol. 2001;314:445–54.CrossRefPubMed
34.
Zurück zum Zitat van Beek E, Hernandez JM, Goldman DA, Davis JL, McLaughlin K, Ripley RT, et al. Rates of TP53 mutation are significantly elevated in African American patients with gastric cancer. Ann Surg Oncol. 2018;25:2027–33.CrossRefPubMedPubMedCentral van Beek E, Hernandez JM, Goldman DA, Davis JL, McLaughlin K, Ripley RT, et al. Rates of TP53 mutation are significantly elevated in African American patients with gastric cancer. Ann Surg Oncol. 2018;25:2027–33.CrossRefPubMedPubMedCentral
35.
Zurück zum Zitat Garcia-Pelaez J, Barbosa-Matos R, Gullo I, Carneiro F, Oliveira C. Histological and mutational profile of diffuse gastric cancer: current knowledge and future challenges. Mol Oncol. 2021;15:2841–67.CrossRefPubMedPubMedCentral Garcia-Pelaez J, Barbosa-Matos R, Gullo I, Carneiro F, Oliveira C. Histological and mutational profile of diffuse gastric cancer: current knowledge and future challenges. Mol Oncol. 2021;15:2841–67.CrossRefPubMedPubMedCentral
36.
Zurück zum Zitat Zhang WH, Zhang SY, Hou QQ, Qin Y, Chen XZ, Zhou ZG, et al. The significance of the CLDN18-ARHGAP fusion gene in gastric cancer: a systematic review and meta-analysis. Front Oncol. 2020;10:1214.CrossRefPubMedPubMedCentral Zhang WH, Zhang SY, Hou QQ, Qin Y, Chen XZ, Zhou ZG, et al. The significance of the CLDN18-ARHGAP fusion gene in gastric cancer: a systematic review and meta-analysis. Front Oncol. 2020;10:1214.CrossRefPubMedPubMedCentral
37.
Zurück zum Zitat Urakami K, Shimoda Y, Ohshima K, Nagashima T, Serizawa M, Tanabe T, et al. Next generation sequencing approach for detecting 491 fusion genes from human cancer. Biomed Res. 2016;37:51–62.CrossRefPubMed Urakami K, Shimoda Y, Ohshima K, Nagashima T, Serizawa M, Tanabe T, et al. Next generation sequencing approach for detecting 491 fusion genes from human cancer. Biomed Res. 2016;37:51–62.CrossRefPubMed
Metadaten
Titel
Molecular profile of poorly cohesive gastric carcinoma with special reference to survival
verfasst von
Yusuke Koseki
Keiichi Hatakeyama
Masanori Terashima
Takeshi Nagashima
Kenichi Urakami
Keiichi Ohshima
Daisuke Aizawa
Takashi Sugino
Kenichiro Furukawa
Keiichi Fujiya
Yutaka Tanizawa
Etsuro Bando
Yukiyasu Okamura
Yasuto Akiyama
Ken Yamaguchi
Publikationsdatum
10.04.2023
Verlag
Springer Nature Singapore
Erschienen in
Gastric Cancer / Ausgabe 4/2023
Print ISSN: 1436-3291
Elektronische ISSN: 1436-3305
DOI
https://doi.org/10.1007/s10120-023-01390-5

Weitere Artikel der Ausgabe 4/2023

Gastric Cancer 4/2023 Zur Ausgabe

Häusliche Gewalt in der orthopädischen Notaufnahme oft nicht erkannt

28.05.2024 Häusliche Gewalt Nachrichten

In der Notaufnahme wird die Chance, Opfer von häuslicher Gewalt zu identifizieren, von Orthopäden und Orthopädinnen offenbar zu wenig genutzt. Darauf deuten die Ergebnisse einer Fragebogenstudie an der Sahlgrenska-Universität in Schweden hin.

Fehlerkultur in der Medizin – Offenheit zählt!

28.05.2024 Fehlerkultur Podcast

Darüber reden und aus Fehlern lernen, sollte das Motto in der Medizin lauten. Und zwar nicht nur im Sinne der Patientensicherheit. Eine negative Fehlerkultur kann auch die Behandelnden ernsthaft krank machen, warnt Prof. Dr. Reinhard Strametz. Ein Plädoyer und ein Leitfaden für den offenen Umgang mit kritischen Ereignissen in Medizin und Pflege.

Mehr Frauen im OP – weniger postoperative Komplikationen

21.05.2024 Allgemeine Chirurgie Nachrichten

Ein Frauenanteil von mindestens einem Drittel im ärztlichen Op.-Team war in einer großen retrospektiven Studie aus Kanada mit einer signifikanten Reduktion der postoperativen Morbidität assoziiert.

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

21.05.2024 TAVI Nachrichten

Bei schwerer Aortenstenose und obstruktiver KHK empfehlen die Leitlinien derzeit eine chirurgische Kombi-Behandlung aus Klappenersatz plus Bypass-OP. Diese Empfehlung wird allerdings jetzt durch eine aktuelle Studie infrage gestellt – mit überraschender Deutlichkeit.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.